All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 650+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Merck & Co. gets positive opinion from EU adcomm (CHMP) for Keytruda combo therapy
Monoclonal antibody, urothelial carcinoma, cancer - Read more

Alpha Cognition’s delayed-released Alzheimer’s med gets on-time approval from FDA
Small molecule, Alzheimer’s disease - Read more

Luye Pharma nabs FDA approval for extended-release schizophrenia med
Small molecule, extended release, schizophrenia - Read more

Anavex to go after EMA approval for Alzheimer’s small molecule
Small molecule, Alzheimer’s - Read more

Guardant Health’s cancer screening blood test OK’d by FDA
Diagnostics, blood test, cancer screening - Read more

THE GOOD
Business Development

Cipher Pharmaceuticals buys a commercial asset from ParaPRO for $89.5M
Small molecule, insecticide, head lice, scabies - Read more

THE GOOD
Clinical Trials

NewAmsterdam Pharma delivers the Ph3 endpoint goods, though investors aren’t entirely impressed
Small molecule, heterozygous familial hypercholesterolemia, cholesterol - Read more

AstraZeneca APLIFYs their Ph3 interim results for leukaemia combo regimen
Small molecule, chronic lymphocytic leukaemia, cancer - Read more

THE GOOD
Fundraises

Spear Bio $45M Series A
Instrumentation, diagnostics, disease research, qPCR - Read more

RetiSpec $10M Series A
Neurodegenerative disease markers, medical AI, eye exam - Read more

THE GOOD
Lawsuits

Indivior agrees to $86M settlement related to opioid epidemic role allegations
Suboxone, small molecule, opioid epidemic - Read more

THE GOOD
Market Reports

Q2 biopharma fundraises continue to trend upward - Read more

THE GOOD
Mergers & Acquisitions

Boehringer Ingelheim acquires checkpoint inhibitor biotech Nerio Therapeutics for up to $1.3B
Small molecule, immuno-oncology, cancer - Read more

Collegium Pharmaceutical acquires Ironshore Therapeutics for $525M
Small molecule, attention deficit hyperactivity disorder (ADHD) - Read more

Repligen acquires Tantti
Instrumentation, bioprocess, chromatography - Read more

THE GOOD
Partnerships

GSK and Flagship Pioneering sign massive drug development partnership, spanning up to 10 novels therapies across respiratory and immunology indications - Read more

THE GOOD
Research

Behavior-altering parasite re-engineered as blood-brain drug delivery vehicle
Toxoplasma gondii, drug delivery - Read more

THE GOOD
Strategic Plans

Roche goes full steam ahead on developing oral alternative to Novo Nordisk and Eli Lilly’s blockbuster weight loss injectables
GLP-1, small molecule, obesity, diabetes - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

Syndax Pharmaceuticals’ leukemia med FDA decision gets delated
Small molecule, leukemia, cancer - Read more

THE BAD
Clinical Trials

Cognition Therapeutics Alzheimer’s med doesn’t SHINE in Ph2
Small molecule, Alzheimer’s disease - Read more

Ventyx Biosciences Crohn’s candidate misses Ph2 primary endpoint, development discontinued
Small molecule, Crohn’s disease - Read more

THE BAD
Earnings & Finances

Wuxi AppTec revenue takes hit in H2 2024, partially due to Biosecure Act implications
CDMO - Read more

THE BAD
Layoffs

Pfizer follows-up last month’s DMD Ph3 failure with 150 layoffs, plus 60 separate layoffs at another site
Gene therapy, Duchenne’s muscular dystrophy, large volume solutions - Read more

Viracta Therapeutics reduces workforce by 23%
Small molecule, lymphoma, cancer - Read more

THE BAD
Market Reports

CDC RSV vaccination criteria narrowing shrinks RSV vaccine market; report
Vaccine, respiratory syncytial virus - Read more

THE BAD
Patient Access

AstraZeneca, Daiichi-Sankyo’s Enhertu not recommended by UK’s NICE due to pricing dispute
Antibody-drug conjugate, breast cancer, drug pricing - Read more

THE UGLY
Clinical Trials

vTv Therapeutics handed FDA clinical hold after “[unresolvable] chromatographic signal” in ADME study prior to Ph3 start
Small molecule, type 1 diabetes - Read more

THE UGLY
Withdrawals & Recalls

Abbott launches voluntarily recall of diabetes monitors that can “provide incorrectly high glucose readings”
Medical device, glucose monitoring, diabetes - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.